Excellere Partners and GHO Capital Sell Biocare Medical to Agilent Technologies
MWN-AI** Summary
Excellere Partners, a Denver-based private equity firm, along with GHO Capital, a specialist investor in global healthcare, has announced that Biocare Medical will be acquired by Agilent Technologies in an all-cash transaction valued at $950 million. The announcement, made on March 9, 2026, highlights Biocare's significant growth trajectory under Excellere and GHO's stewardship, achieving double-digit revenue and profit growth annually since 2021.
Biocare Medical is recognized as a leader in immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) solutions, with a strengthened core business and expanded molecular diagnostics capabilities. This strategic acquisition aligns well with Agilent's focus on life sciences, particularly cancer diagnostics, and is expected to enhance the capabilities of both companies. Agilent aims to leverage its global reach to expand market access for Biocare and bolster innovation.
The leadership from Excellere and GHO emphasized their commitment to supporting Biocare's management in achieving significant growth. Luis de Luzuriaga, CEO of Biocare, expressed excitement about the acquisition, noting that combining their capabilities with Agilent will enhance operational scale and innovation and ultimately improve customer service and patient care.
The transaction is subject to regulatory approvals and closing conditions. Jefferies acted as the exclusive financial advisor for Excellere and GHO, while Barclays served as the advisor for Agilent along with other legal counsel. This acquisition represents a milestone for Biocare, positioning the company to continue its growth in the healthcare market while benefiting from the resources and expertise of Agilent Technologies.
MWN-AI** Analysis
The recent acquisition of Biocare Medical by Agilent Technologies for $950 million marks a significant development in the life sciences sector, particularly in immunohistochemistry and molecular diagnostics. This move follows a period of impressive growth for Biocare under the stewardship of Excellere Partners and GHO Capital, characterized by double-digit revenue and profitability increases since 2021.
For investors, this transaction could signal a bullish sentiment toward companies operating at the intersection of healthcare and technology. Agilent, with a strong foundation in life sciences and diagnostics, is well-positioned to leverage Biocare’s advanced capabilities in cancer diagnostics to enhance its product offerings. As Agilent integrates Biocare's technologies, this could lead to accelerated innovation and improved service delivery, affording them a competitive edge.
Investors should consider the long-term implications of this acquisition. Biocare’s established reputation and its recent growth trajectory suggest it can operate synergistically with Agilent, potentially unlocking new market opportunities and enhancing customer access globally. The alignment of missions focused on quality and innovation in cancer diagnostics reinforces the strategic logic behind the buyout.
From a financial perspective, while the $950 million all-cash transaction initially appears steep, the potential for future earnings growth and enhanced market share justifies the investment. Moreover, given Agilent's proven track record in expanding its portfolio through strategic acquisitions, this move could lead to significant returns over the upcoming years.
In conclusion, the acquisition of Biocare by Agilent highlights key trends in the healthcare sector, where strategic partnerships and innovation are essential for growth. For investors looking for opportunities in life sciences technologies, this transaction exemplifies the type of strategic movements that may yield substantial value in the evolving healthcare landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Agilent to acquire Biocare in an all-cash transaction valued at $950 million
- Transaction follows significant period of growth under Excellere Partners and GHO Capital stewardship, with annual double-digit revenue and profit growth since 2021
Denver, CO and London, UK, 9 March 2026: Excellere Partners (“Excellere”), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, GHO Capital Partners LLP (“GHO”), a specialist investor in global healthcare, and Biocare Medical (“Biocare”), a global leader of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions, today announce that Biocare has entered into an agreement to be acquired by Agilent Technologies (“Agilent”, NYSE:A), a prominent player in life sciences, diagnostics, and applied chemical markets.
Biocare has grown significantly under Excellere and GHO’s ownership. Since 2021, the company has achieved annual double-digit revenue and profitability growth through the strengthening of its core IHC business, expanding into molecular diagnostics via acquisition, whilst reinforcing executive leadership. Biocare has now become a recognized specialist in IHC, ISH, and FISH with a high-quality antibody business and strong commercial, regulatory and R&D capabilities.
With a focus on serving life sciences and diagnostics and a particular expertise in cancer diagnostics, Agilent’s strategy closely aligns with that of Biocare and the transaction is expected to expand the complementary capabilities of both businesses. The acquisition will enable Biocare to grow from a position of strength, building on its existing customer solutions and maintaining a strong focus on world-class quality and innovation.
In a joint statement, Excellere and GHO conveyed their gratitude and appreciation in supporting the Biocare team over the last several years: “Working closely with Luis and the Biocare management team, we have been proud to support their significant growth and success by applying our tried and tested growth playbook and leveraging our deep expertise and network in life science tools and diagnostics to build the company into the successful global business it is today. With its exceptional team and strengthened capabilities, Biocare has developed into a recognized leading innovator in IHC solutions, improving the diagnosis and treatment of patients. As it continues its growth trajectory, we are pleased to have found the right partner in Agilent - one that can utilize its global reach and resources to unlock even greater market access, enhanced customer support, and accelerated innovation for Biocare’s customers worldwide.”
Luis de Luzuriaga, Chief Executive Officer at Biocare Medical, commented: “The acquisition by Agilent is an exciting milestone for Biocare. By joining Agilent and combining our complementary capabilities in cancer diagnostics, we will expand our operational scale, accelerate innovation, and enhance the level of service we provide to customers and partners – ultimately benefiting the patients we serve. After years of significant progress, this is the right time to move forward with new ownership aligned with our commitment to product quality, clinical impact, and value creation. I would like to thank our investors, Excellere Partners and GHO Capital, whose support and counsel have been instrumental in building Biocare into the company it is today.”
The transaction is subject to closing conditions and the receipt of transaction-related regulatory approvals.
Jefferies is serving as exclusive financial advisor and Ropes & Gray LLP is serving as legal advisor to Excellere Partners and GHO Capital. ICR Healthcare is serving as strategic communications advisor to GHO Capital.
Barclays is serving as financial advisor, Sullivan & Cromwell LLP is serving as legal advisor and Joele Frank is serving as strategic communications advisor to Agilent.
###
About Excellere Partners
Excellere Partners is a Denver-based private equity firm with $2.3 billion of committed capital across four funds that specialize in partnering with entrepreneurs and management teams through growth recapitalizations and management buyouts. The firm employs a research-driven, top-down investment strategy and supports its entrepreneurs and management teams with a proprietary value-creation process designed to enhance the corporate and operational infrastructure for scalability and growth. Excellere’s investments are focused on emerging growth companies positioned to benefit from industry consolidation and favorable macroeconomic and demographic trends. The Firm’s targeted industry sectors include healthcare, industrial growth, and business services. For more information about Excellere, please visit https://www.excellere.com
About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor headquartered in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalization to build businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.
For further information or queries, please contact
Excellere Partners media enquiries
Tracie Kelly
Tel: +1 (303)-765-2374
tkelly@excellere.com
GHO Capital media enquiries
ICR Healthcare
Amber Fennell, Angela Gray, Kris Lam
Tel: +44 (0) 20 3709 5700
ghocapital@icrhealthcare.com
FAQ**
How does Agilent Technologies Inc. A plan to integrate Biocare's operations and workforce to maximize synergies and drive continued double-digit revenue growth post-acquisition?
What specific strategies will Agilent Technologies Inc. A implement to enhance Biocare's innovative capabilities and expand its product offerings in cancer diagnostics?
Can Agilent Technologies Inc. A provide details on the expected timeline for regulatory approvals and the anticipated impact on Biocare's current customer base during the transition?
What measures will Agilent Technologies Inc. A take to maintain Biocare’s commitment to world-class quality and customer service throughout the acquisition process?
**MWN-AI FAQ is based on asking OpenAI questions about Agilent Technologies Inc. (NYSE: A).
NASDAQ: A
A Trading
1.38% G/L:
$116.47 Last:
769,948 Volume:
$115.51 Open:
